Lex is a premium daily commentary service from the Financial Times. It helps readers make better investment decisions by highlighting key emerging risks and opportunities. Click here to read more international insights.
The news from Denmark’s sizable pharmaceuticals sector has been suitably Nordic Noir recently. H Lundbeck, beset by patent expiry woes, had the mother of all profit warnings at the end of last year. And Novo Nordisk got a “don’t call us, we’ll call you” note from the U.S. Food and Drug Administration in February, asking for more tests for Tresiba, its insulin drug on which great hopes are pinned. The setbacks sent the shares of both companies down sharply. But time moves on. First-quarter numbers on Wednesday suggest that they are over the worst.